CMaT Hosts Interactive Course to Explore Regenerative Medicine, Cell Manufacturing, and Society

Achievement date: 
2018
Outcome/accomplishment: 

A new, multi-institutional course on the ethical, policy, and societal implications of cell therapies was introduced by the Cell Manufacturing Technologies (CMaT) Center – a National Science Foundation (NSF) sponsored Engineering Research Center (ERC) headquartered at the Georgia Institute of Technology (GT).

Impact/benefits: 

The new CMaT course incorporates multiple perspectives on cell therapies by leveraging a team-teaching approach. Ten experts both within and external to CMaT promoted their core insights with the intention of challenging participants to develop and “train in the key skill sets prioritized by [CMaT’s] industry and clinical partners.” Together, the group explored “good manufacturing practices” for real-world applications and evolved a shared CMaT knowledge base.

Explanation/Background: 

CMaT joins research efforts across GT, the University of Georgia (UGA), the University of Wisconsin-Madison (UW), and the University of Puerto Rico at Mayagüez (UPRM) with the goal of transforming the manufacture of cell-based therapeutics into a large-scale, lower-cost, reproducible, and high-quality engineered process for broad industry and clinical use. Together in partnership with the National Cell Manufacturing Consortium, CMaT collaborates with additional partners, including Emory University (EU), Osaka University (OU), the University of Oregon (UO), Penn Medicine, Gladstone Institutes, Curam, and CCRM. A total of 28 students from six CMaT sites were enrolled in the introductory course as a learning community. Students further connected across sites through team-based final projects.